Metabolic effects of pioglitazone and sodium-glucose cotransporter 2 inhibitors in familial partial lipodystrophy
Acta Diabetologica · 2025
DOI: 10.1007/s00592-025-02633-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Diabetologica, 2025. Verfasst von Utku Soyaltin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism Disorders, Department of Internal Medicine, Faculty of Medicine, Ege University, Izmir, Turkey. soyaltinutku…. Hauptthemen laut MEDLINE: Pioglitazone, Sodium-Glucose Transporter 2 Inhibitors, Lipodystrophy, Familial Partial, Hypoglycemic Agents. Die Arbeit nennt 36 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: We aimed to evaluate the potential metabolic benefits of pioglitazone, a PPARG agonist, and sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with familial partial lipodystrophy (FPLD). METHODS: This retrospective medical chart study included 38 adult patients with FPLD (18 treated with pioglitazone and 20 with SGLT2 inhibitors). RESULTS: Treatment with pioglitazone reduced HbA1c from 8.6% (6.2-9.2) to 7.0% (5.9-8.8) at month 6 (p = 0.004) and 7.0% (6.1-8.7) at month 12 (p = 0.107). Triglycerides decreased by 25% (6-55%) at month 6 (p = 0.001) and 16% (4-44%) at month 12 (p = 0.008). A modest reduction in ALT was observed at month 12 (p= 0.046). Treatment with SGLT2 inhibitors reduced HbA1c from 8.7% (7.9-10.2) at baseline to 8.1% (7.4-9.4) at month 6 (p = 0.003) and 7.9% (7.3-8.9) at month 12 (p = 0.003). Median triglyceride levels decreased by 11% (0-33%) at month 6 (p = 0.013), while changes at month 12 were not significant. No meaningful changes were observed in weight, ALT, or AST. CONCLUSIONS: We observed modest metabolic improvements following treatment with pioglitazone and SGLT2 inhibitors in patients with FPLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology and Metabolism Disorders, Department of Internal Medicine, Faculty of Medicine, Ege University, Izmir, Turkey. soyaltinutku@hotmail.com.
- Division of Endocrinology and Metabolism Disorders, Department of Internal Medicine, Faculty of Medicine, Ege University, Izmir, Turkey.
- Izmir Biomedicine and Genome Center & DEPARK, Dokuz Eylul University Health Campus, Izmir, Turkey.
Zitieren
APA
Soyaltin, U., Simsir, I. Y., & Akinci, B. (2025). Metabolic effects of pioglitazone and sodium-glucose cotransporter 2 inhibitors in familial partial lipodystrophy. Acta Diabetologica. https://doi.org/10.1007/s00592-025-02633-w
Vancouver
Soyaltin U, Simsir IY, Akinci B. Metabolic effects of pioglitazone and sodium-glucose cotransporter 2 inhibitors in familial partial lipodystrophy. Acta Diabetologica. 2025. doi:10.1007/s00592-025-02633-w
BibTeX
@article{Soyaltin2025,
author = {Soyaltin, Utku and Simsir, Ilgin Y and Akinci, Baris},
title = {Metabolic effects of pioglitazone and sodium-glucose cotransporter 2 inhibitors in familial partial lipodystrophy},
journal = {Acta Diabetologica},
year = {2025},
doi = {10.1007/s00592-025-02633-w}
}
EUVIMED